not used title
not used title
This year, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections.
I had the opportunity to connect with Paul Perreault, CEO and Managing Director of CSL Limited, the world’s third largest biotech, about the company’s efforts to address COVID-19.
Stephen Ubl (SU): Paul, thanks for taking the time. We have all learned a lot over the last year and these lessons learned will serve us well moving forward. At CSL, you know all about that – weren’t you founded to aid in the fight against the last global pandemic, the 1919 influenza?
Paul Perreault (PP): That’s right. Since our start in 1916 during World War I, we have been driven by our promise to help patients and protect public health. In fact, our legacy in fighting infectious disease goes back even further to 1901, when Emil von Behring, one of the founders of CSL Behring, won the first Nobel Prize in Medicine for pioneering the use of plasma to treat patients suffering from diphtheria.
As we’ve grown into the third-largest biotech in the world, we have viewed ourselves as an organization that strives to be in constant advancements. We need to keep moving and changing shape to meet the evolving needs of our patients, and of course, the times.
The current pandemic is certainly one of the worst global health care crises we’ve experienced in our lifetime, but we’ve also seen over the past year what can happen when people across the scientific community, government, academia and industry work together in new ways.
The role of science in solving problems has been highlighted like never before and I think this crisis has shown us that we are more resilient and adaptable than we ever imagined ourselves to be.
SU: That’s incredible. You touched on this; can you expand on the work you are doing directly related to addressing COVID-19?
PP: Just like many organizations throughout our industry, CSL needed to be agile and adapt to the evolving environment that quickly became all things COVID a year ago – both operationally as well as applying our science and capabilities in response to the pandemic.
Most of us have had friends, family members and colleagues impacted by COVID, so the sense of urgency is lost on no one.
Since the start of the pandemic, we have very deliberately focused our energies on matching our science with our technical capabilities and facilities around the world. Monoclonal antibodies, hyperimmunes and vaccines – they are all in our wheelhouse. In fact, if you created an organization with the inherent capabilities to respond to COVID-19, the organization would look a lot like CSL.
We currently have multiple R&D programs underway focused on fighting COVID-19 and we are very fortunate and privileged to be able to commit to this work across several different areas.
We are one of the founding members of the CoVIg-19 Plasma Alliance to develop a potential plasma-derived hyperimmune therapy in the US and Europe. A Phase 3 trial began in October. We’re also working on a similar plasma product for the Australian market to be known as COVID-19 Immunoglobulin and this is under development at one of our Australia sites.
We also have an agreement in place with AstraZeneca and the Australian government to manufacture 50 million doses of the Oxford University / AstraZeneca vaccine candidate, and we’re on track to have the first of those doses ready for distribution – subject to TGA approval – in the second half of March.
Our Seqirus influenza vaccines business is also working to protect public health and help prevent what has been called – the ‘twindemic’– through our flu vaccines portfolio.
I’m heartened by the continued collaboration our industry has demonstrated and I think I can speak for everyone in biotech when we say that fighting COVID-19 is personal for all of us.
SU: It has been incredible to watch these partnerships – both public and private – form so quickly to rise to the challenge. It really underscores our industry’s commitment to patients. As a company operating in the rare disease space, can you share more about the patient-centric approach you take?
In our industry, being patient focused runs deep. We often talk about how each of our more than 27,000 employees at CSL come to work every day like someone’s life depends on it, because it really does.
Our medicines for people living with rare and serious diseases are not discretionary -- they are a necessity. Our role in ensuring patients have access to these medicines is an imperative, not an afterthought.
In the United States alone, the National Organization for Rare Disorders (NORD) estimates that more than 7,000 rare diseases affect 25-30 million Americans. That means one in 10 Americans are suffering from a rare disease and more than half of those patients are children. Too often people with a rare disease struggle to receive a proper diagnosis, find information or get the proper treatment.
At CSL our values of patient focus, superior performance, innovation, integrity and collaboration underscore our commitment to support the rare disease community — not only through our science and therapies, but also through our partnerships and collaborations with academic institutions and patient advocacy groups.
As always, you can stay up-to-date with the work the biopharmaceutical industry is doing to combat COVID-19 here.
Stephen J. Ubl
Stephen J. Ubl is president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America’s leading biopharmaceutical research companies. The U.S. biopharmaceutical sector directly employs more than 800,000 Americans and invests more than $100 billion in research and development annually – more than any other industry in America.
Ubl leads PhRMA’s work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. Ubl is recognized around the world as a leading health care advocate and policy expert who collaborates successfully with diverse stakeholder groups – including patient and physician groups, regulators, public and private payers, and global trade organizations – to help ensure timely patient access to innovative treatments and cures. The New York Times writes, “If anyone can find areas of agreement with the critics, or at least work productively with them, it may be Mr. Ubl. He is more conversant with the intricacies of health policy, and more adept at the politics."
Previously, Ubl served as president and CEO of medical technology association AdvaMed, where he helped facilitate landmark reforms related to the U.S. Food and Drug Administration product review process and Medicare’s coverage and reimbursement of medical technologies. He led the industry’s defense of breakthrough R&D, successfully delaying an innovation-stifling device tax, and, in 2013, was recognized by a leading industry publication as one of 10 people to have a lasting impact on the medical technology industry.
Ubl has worked extensively with patient advocacy organizations in health policy, including longstanding service on the board of the National Health Council, a leading umbrella organization for voluntary health care organizations and has been personally involved with JDRF (formerly known as the Juvenile Diabetes Research Foundation).
He is routinely recognized as one of Washington’s most effective advocates. Ubl has been recognized on Business Insider’s “DC Healthcare Power Players” and Modern Healthcare’s “100 Most Influential People in Healthcare.” He is identified as a top health influencer by Medical Marketing & Media and PR Week magazines.
https://x.com/steveubl
https://www.linkedin.com/in/steveubl/
President and Chief Executive Officer
Why smart vaccine policy matters
August 3, 2026
New study: HPV vaccination helps prevent cervical cancer deaths
July 21, 2026
Staffing up: Building the future biopharma workforce to keep America in the lead
June 29, 2026
Nearly 80 researchers advocate on Capitol Hill
June 11, 2026
New research reinforces the importance of hepatitis B vaccination at birth
May 21, 2026
World Immunization Week: Putting preventable diseases in the past
April 24, 2026
ICYMI: Measles resurgence could cost U.S. nearly $8 billion over five years
April 15, 2026
Why shifting childhood vaccines to “shared clinical decision-making” puts kids at risk
February 23, 2026
Congratulations to our 2026 Working for Cures Employee Champions
January 29, 2026
Changes to America’s childhood vaccine schedule fail to protect our nation's kids
January 13, 2026
New study: Measles setbacks harm health and America’s economy
October 28, 2025
Why the hepatitis B vaccine matters
October 21, 2025
Manufacturing U.S. jobs and breakthroughs
October 6, 2025
Historic biopharmaceutical investments: A prescription for America’s future
September 29, 2025
Vaccines and autism: Decades of scientific evidence find no link
September 22, 2025
Why the vaccine injury program matters
August 18, 2025
Recognizing the importance of vaccination for American health and security
August 4, 2025
Bringing to life the full story of biopharmaceutical innovation and investments
July 22, 2025
Answering common questions on mRNA technology
July 17, 2025
What to know about vaccine ingredients: Aluminum and thimerosal
June 24, 2025
World Immunization Week: Highlighting the importance of vaccines for public health
April 28, 2025
From sound to science: How IP powers innovation in music and hearing
April 25, 2025
What you need to know: Measles and the MMR vaccine
March 10, 2025
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
February 25, 2025
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
February 3, 2025
Recognizing the value of disease prevention with Dr. Len Friedland from GSK
December 12, 2024
Congratulations to our 2024 Working for Cures Employee Champions
December 11, 2024
Leveraging the power of vaccines to prevent antimicrobial resistance
October 31, 2024
From the emergency department to the CDC Advisory Committee: Key takeaways from ACIP’s recent meeting
October 30, 2024
The Patient Perspective: Vaccines
October 23, 2024
The importance of partnership: A conversation with Takeda
October 10, 2024
New research: American biopharmaceutical investment in R&D drives transformational innovation
September 16, 2024
How to protect your children’s health this school year
August 22, 2024
New Report: Vaccines continue to drive improved health outcomes
July 16, 2024
The future of oncology R&D lies in policymakers’ hands
July 8, 2024
More than 60 researchers advocate on Capitol Hill
July 1, 2024
Showcasing the promise of biopharma at ASCO 2024
June 28, 2024
Alzheimer's & Brain Awareness Month: A conversation with Biogen
June 27, 2024
Alzheimer's & Brain Awareness Month: A conversation with Eisai
June 24, 2024
Alzheimer's & Brain Awareness Month: A conversation with Eli Lilly and Company
June 20, 2024
World Vaccine Congress: Building on vaccine success
April 1, 2024
Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer
January 30, 2024
New poll: Americans agree that expanding the TRIPS waiver will harm U.S. global manufacturing and innovation leadership
January 29, 2024
Congratulations to our 2023 Working for Cures Employee Champions
December 6, 2023
Watch: Putting patients front and center for World AIDS Day
November 30, 2023
WHO Pandemic Agreement offers opportunities and risks for American innovators
November 20, 2023
New Report: 1,600 cancer treatments and vaccines in clinical development
November 9, 2023
What you should know about protecting your health this fall
October 16, 2023
What you need to know: COVID-19 public health emergency is over, but ideological attacks on IP remain
September 12, 2023
Watch: New video series spotlights advances in biopharmaceutical science
August 24, 2023
Key considerations as Congress works towards PAHPA reauthorization
July 12, 2023
New report shows high-impact R&D happens after cancer medicines are first approved
July 10, 2023
A conversation with Dr. Mike Ybarra on the current state of COVID-19
June 27, 2023
More than 60 researchers ask Congress to support innovation
June 26, 2023
Biopharmaceutical science powered by PRIDE
June 16, 2023
Addressing Mental Health: A conversation with Barry Greene, CEO of Sage Therapeutics
May 30, 2023
World IP Day 2023: Celebrating women leaders in innovation
April 26, 2023
What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary
April 13, 2023
PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement
March 30, 2023
Celebrating the success of the COVID-19 vaccines, and looking to the future
March 27, 2023
PhRMA submits comments to OSTP on enhancing clinical trial diversity
March 21, 2023
What we’ve learned from three years of fighting COVID-19
March 20, 2023
U.S. must address IP and market access barriers abroad to protect American innovation
January 31, 2023
WTAS: Inflation Reduction Act already impacting R&D decisions
January 17, 2023
Sparking conversations — and careers — at the 2nd annual Pathways to Success Summit
December 8, 2022
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
December 1, 2022
Word of the Month: What is TRIPS?
November 29, 2022
What you should know about RSV
November 15, 2022
TRIPS waiver expansion risks public health
November 14, 2022
Congratulations to our 2022 Working for Cures Employee Champions
November 10, 2022
Expanding the WTO intellectual property waiver will hurt American jobs
November 9, 2022
Word of the Month: Long COVID
October 19, 2022
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus
October 13, 2022
Partnerships are driving global COVID-19 treatment access
September 22, 2022
The dangers of expanding the TRIPS waiver
September 19, 2022
ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines
August 16, 2022
An open letter to Congress: Stand with patients and future cures
August 4, 2022
PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021
July 18, 2022
ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies
July 15, 2022
Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance
July 14, 2022
COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs
July 7, 2022
ICYMI: Antimicrobial resistance spotlighted as growing public health threat
July 6, 2022
Biopharmaceutical researchers to discuss the value of R&D with Congress
June 9, 2022
Intellectual Property waiver on COVID-19 innovation is unnecessary and harmful
May 23, 2022
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
May 13, 2022
ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond
May 9, 2022
A conversation with Barry Greene, CEO of Sage Therapeutics
May 4, 2022
ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19
April 28, 2022
Stephanie Dyson of BMS on reducing health disparities
April 27, 2022
Biopharmaceutical industry drives economic growth in all 50 states
March 14, 2022
New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year
February 24, 2022
What you need to know about newly authorized COVID-19 antiviral treatments
February 22, 2022
Guest post: Joining forces to combat the COVID-19 mental health crisis
February 17, 2022
Guest Blog: COVID-19 vaccines are the key to keeping kids healthy
February 16, 2022
Protecting U.S. innovation abroad to support economic and pandemic recovery
February 1, 2022
ICYMI: New report demonstrates growing global impact of antimicrobial resistance
January 24, 2022
Navigating the patient experience in the time of COVID-19
December 6, 2021
Global COVID-19 vaccination matters now and for the future
November 29, 2021
Understanding breakthrough COVID-19 infections
November 11, 2021
PhRMA submission to 2022 National Trade Estimate Report underscores need for pro-innovation U.S. trade policy to combat COVID-19
October 29, 2021
The important role of antivirals in the fight against COVID-19
October 6, 2021
Understanding Long COVID-19
September 29, 2021
Upcoming graduate student summit will showcase pathways to success within the biopharmaceutical industry
September 28, 2021
Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda
September 27, 2021
Industry leaders discuss the impact of the drug pricing debate
September 23, 2021
A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19
September 8, 2021
The impact of monoclonal antibodies and COVID-19 recovery
September 2, 2021
Recognizing National Immunization Awareness Month
August 31, 2021
Driving further innovation is critical to global vaccine equity
August 24, 2021
Supporting country readiness to boost global vaccine access
August 12, 2021
Ensuring global vaccine equity requires eliminating trade and regulatory barriers
August 5, 2021
Setting the record straight: Addressing common misconceptions about the COVID-19 vaccine
August 4, 2021
Increasing global access to vaccines by optimizing production
July 29, 2021
Guest post: Retired medics return to the field to take on vaccine delivery and disaster relief
July 23, 2021
PhRMA member companies’ R&D investments reach record high of $91.1 billion in 2020
July 22, 2021
Guest Post: A patient’s story of the long-term health impacts of COVID-19
July 21, 2021
Dose sharing as a part of the COVID-19 global vaccine equity strategy
July 20, 2021
Promoting global vaccine equity while protecting innovation
July 15, 2021
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
July 2, 2021
PhRMA awards $75,000 to fund initiatives to reduce health inequities
July 1, 2021
Watch: Building trust and enhancing clinical trial diversity
June 24, 2021
Building a better health care system: A conversation with Mark Reisenauer, President of Astellas US
June 23, 2021
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
June 22, 2021
Americans 12 years of age and older are eligible for COVID-19 vaccines
June 17, 2021
Researchers to shine light on biopharmaceutical R&D with policymakers
June 15, 2021
PhRMA hosts first stakeholder workshop on clinical trial diversity
June 11, 2021
Coming together to fight COVID-19: A conversation with Barry Greene, CEO of Sage Therapeutics
June 9, 2021
A year later: Reflections on the meaning of equity
May 25, 2021
ICYMI: PhRMA president and CEO Stephen J. Ubl joins other industry leaders for a conversation on COVID-19 vaccines with Axios
May 21, 2021
Supporting India during the devastating coronavirus surge
May 20, 2021
New polling shows Americans are sounding the alarm on the TRIPS IP waiver
May 14, 2021
The Biden Administration allows politics to upend a pragmatic pandemic response
May 14, 2021
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
May 6, 2021
Ron Busby, Sr., President and CEO of the U.S. Black Chambers, Inc. on improving vaccine confidence in community
May 5, 2021
Reflecting on Mental Health Awareness Month
May 4, 2021
American leadership on innovation policy is essential to global health progress
May 4, 2021
Patient safety is at the heart of COVID-19 vaccine R&D
April 26, 2021
Data shows that Americans are relying on vaccines to get us through the pandemic
April 22, 2021
ICYMI: New CBO Report highlights biopharmaceutical leadership in the development of new treatments and cures
April 12, 2021
Diversifying clinical trials and fighting disease requires equity and trust
April 12, 2021
Building confidence in the COVID-19 vaccine through education
March 22, 2021
ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
March 8, 2021
Intellectual property is the key to vaccine development, manufacturing and technology sharing
March 5, 2021
Key takeaways: PhRMA comments to USPTO on how to make the innovation ecosystem more diverse and inclusive
March 5, 2021
Fighting variants of COVID-19
February 22, 2021
ICYMI: Report provides actionable recommendations to strengthen America’s preparedness and future health crises response
February 22, 2021
Top five issues voters want addressed in the administration’s first 100 days
February 18, 2021
The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing
February 12, 2021
Lessons learned from COVID-19: The way we develop new medicines is changing
February 10, 2021
Guest post: PhRMA talks racial and health equity with Stephanie Dyson, Head of Office at Biogen
January 28, 2021
Growing trend: Increased vaccine confidence
January 28, 2021
Election insights: Common ground areas to address Americans’ health care concerns
January 26, 2021
Paper finds gaps in health data are a barrier to health equity
January 11, 2021
New research shows hotspots of inequity relate to increased COVID-19 hospitalizations
January 8, 2021
American biopharmaceutical manufacturing: Fueling economic growth now and for years to come
December 21, 2020
Election insights: Voter priorities in the states
December 17, 2020
Report highlights biopharmaceutical industry’s commitment to D&I
December 17, 2020
Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US
December 16, 2020
Insights from the election: Meeting voters where they are on health care
December 15, 2020
Coming together to fight COVID-19: A conversation with Kabir K. Nath, President & CEO of Otsuka North America Pharmaceutical Bu
December 9, 2020
Guest post: How COVID-19 underscores the importance of public confidence in vaccines
December 7, 2020
Guest Post: Bringing our best to the fight against COVID-19
December 3, 2020
An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb
November 18, 2020
Deep dive: The issues that drove the 2020 vote
November 13, 2020
Understanding the emergency use authorization process for COVID-19 vaccines
November 12, 2020
ICYMI: Addressing health inequities: Biopharmaceutical companies are rising to the occasion
November 2, 2020
U.S. trade policy must prioritize American biopharmaceutical innovation and patient access
November 2, 2020
Voters want to address the real drivers of health care costs for patients and the system
November 2, 2020
Coming together to fight COVID-19: A conversation with Peter Anastasiou, Executive Vice President of Lundbeck
October 28, 2020
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
October 13, 2020
New Report: The biopharmaceutical industry’s sustained commitment to inspiring and advancing tomorrow’s STEM workforce
October 12, 2020
Flu Season 2020: Why it’s time to talk to your doctor today about getting a flu shot
October 8, 2020
Coming together to fight COVID-19: A conversation with Alexander Hardy, CEO of Genentech
October 1, 2020
Leading researchers to spotlight the critical role of biopharmaceutical R&D
October 1, 2020
Why the U.S. biopharmaceutical industry is leading the charge against COVID-19
September 30, 2020
Coming together to fight COVID-19: A conversation with Ramona Sequeira, President of Takeda Pharmaceuticals U.S.A
September 23, 2020
Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.
September 17, 2020
Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19
September 16, 2020
PhRMA member companies invested $83 billion in research and development last year
September 10, 2020
Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi
September 2, 2020
Three ways the pharmaceutical industry can positively impact health equity
September 1, 2020
The 2020 We Work for Health Champion Awards showcase the best of our industry
August 27, 2020
Summer reading in the age of COVID-19
August 21, 2020
Supporting access to vaccines for Part D beneficiaries
August 12, 2020
The patient perspective navigating COVID-19
August 11, 2020
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19
August 4, 2020
Executive order threatens R&D when we need it most to fight COVID-19
July 30, 2020
The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19
July 22, 2020
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
July 21, 2020
New report explores setbacks that bring future cancer success stories
July 16, 2020
R&D Focus: 5 things to know about the biopharmaceutical research ecosystem
July 13, 2020
PhRMA’s Lori Reilly joined CSG to discuss the industry’s response to COVID-19 and what it means for states
July 13, 2020
New initiative to bridge the gap on antimicrobial innovation
July 9, 2020
Guest Post: Pride started with protest: Combatting the dual pandemics of COVID-19 and racism this Pride Month
June 30, 2020
How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective
June 29, 2020
In combating COVID-19, science is how we get back to normal
June 24, 2020